Citadel Advisors
LNAI

Citadel Advisors’s Lunai Bioworks LNAI Stock Holding History

Citadel Advisors’s Portfolio LNAI Stock Details LNAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-291
Closed -$12.7K – 14652
2025
Q1 		$12.7K Sell
291
-324
-53% -$20.7K ﹤0.01% 13431
2024
Q4 		$41.1K Buy
615
+577
+1,518% +$38.3K ﹤0.01% 12594
2024
Q3 		$1.45K Buy
+38
New +$2.63K ﹤0.01% 13850
2023
Q4 		– Sell
-4
Closed -$1.34K – 15086
2023
Q3 		$1.34K Buy
+4
New +$608 ﹤0.01% 13883
2023
Q1 		– Sell
-21
Closed -$1.75K – 15383
2022
Q4 		$1.75K Buy
+21
New +$2.82K ﹤0.01% 14422
2022
Q3 		– Sell
-493
Closed -$76K – 13445
2022
Q2 		$76K Buy
+493
New +$226K ﹤0.01% 11638
2021
Q4 		– Sell
-138
Closed -$74K – 14586
2021
Q3 		$74K Buy
+138
New +$67.4K ﹤0.01% 13124

Other funds holding LNAI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's LNAI Position: Q1 2026 in Review

Citadel Advisors sold out of Lunai Bioworks (LNAI) in Q1 2026, closing a stake of 2,579 shares — an estimated $18.2K sold.

Citadel Advisors first reported a position in LNAI in Q1 2021 and held it in 9 quarters. The position peaked at $476K in Q1 2022. 27 funds tracked by Wall St. Rank hold LNAI as of Q1 2026.

  • Citadel Advisors reported no remaining Lunai Bioworks position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 2,579 Lunai Bioworks shares in Q1 2026, an estimated $18.2K.
  • Citadel Advisors first reported a position in Lunai Bioworks in Q1 2021 and held it in 9 quarters.
  • Citadel Advisors's Lunai Bioworks position peaked at $476K in Q1 2022.
  • 27 funds tracked by Wall St. Rank held Lunai Bioworks as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.